Biologics, with their precision targeting, expand treatment options for a multitude of diseases - from cancer to autoimmune disorders. In 2023 alone, 10 antibody therapeutics received their first ...
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this ...
News-Medical.Net on MSN
Optibrium delivers real-time collaboration in its comprehensive molecular design platform with StarDrop 8
Optibrium, a leading developer of software and AI solutions for molecular design, today announced the release of StarDrop 8, ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody ...
Researchers at Harvard Medical School developed a tool that uses artificial intelligence to accelerate drug discovery and development. The new technology, called PDGrapher, applies machine learning to ...
Advances in drug discovery and development depend on robust and reliable data as well as the ability to analyze and leverage insights from huge volumes of data produced through increasingly automated ...
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage ...
LONDON, May 8 (Reuters) - Google Deepmind has unveiled the third major version of its "AlphaFold" artificial intelligence model, designed to help scientists design drugs and target disease more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback